Format

Send to

Choose Destination
JAMA Pediatr. 2018 Nov 5:e182302. doi: 10.1001/jamapediatrics.2018.2302. [Epub ahead of print]

Clinical Utility of Reinterpreting Previously Reported Genomic Epilepsy Test Results for Pediatric Patients.

Author information

1
Department of Pathology, University of Texas Southwestern Medical Center, Dallas.
2
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas.
3
Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas.
4
Eugene McDermott Center for Human Growth & Development, University of Texas Southwestern Medical Center, Dallas.
5
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.

Abstract

Importance:

Clinical genomic tests that examine the DNA sequence of large numbers of genes are commonly used in the diagnosis and management of epilepsy in pediatric patients. The permanence of genomic test result interpretations is not known.

Objective:

To investigate the value of reinterpreting previously reported genomic test results.

Design, Setting, and Participants:

This study retrospectively reviewed and reinterpreted genomic test results from July 1, 2012, to August 31, 2015, for pediatric patients who previously underwent genomic epilepsy testing at a single tertiary care pediatric health care facility. Reinterpretation of previously reported variants was conducted in May 2017.

Main Outcomes and Measures:

Patient reports from clinical genomic epilepsy tests were reviewed, and all reported genetic variants were reinterpreted using 2015 consensus standards and guidelines for interpreting hereditary genetic variants. Three classification tiers were used in the reinterpretation: pathogenic or likely pathogenic variant, variant of uncertain significance (VUS), or benign or likely benign variant.

Results:

A total of 309 patients had genomic epilepsy tests performed (mean [SD] age, 5.6 [0.8] years; 163 [52.8%] male), and 185 patients had a genetic variant reported. The reported variants resulted in 61 patients with and 124 patients without a genetic diagnosis (VUS variants only). On reinterpretation of all reported variants, 67 of the 185 patients (36.2%) had a change in variant classification. Of the 67 patients with a genetic variant change in interpretation, 21 (31.3%) experienced a change in diagnosis. During the 5 years of the study, 19 of 61 patients (31.1%) with a genetic diagnosis and 48 of 124 patients (38.7%) with undiagnosed conditions (VUS only) had their results reclassified. Review of genomic reports issued during the final 2 years of the study identified reclassification of variants in 4 of 16 patients (25.0%) with a pathogenic or likely pathogenic variant and 11 of 41 patients (26.8%) with a VUS.

Conclusions and Relevance:

The identified high rate of reinterpretation in this study suggests that interpretation of genomic test results has rapidly evolved during the past 5 years. These findings suggest that reinterpretation of genomic test results should be performed at least every 2 years.

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center